Turofexorate isopropyl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319832

CAS#: 629664-81-9

Description: Turofexorate isopropyl, also known as WAY-362450 and XL335, is a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR) (EC(50) = 4 nM, Eff = 149%), which attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.

Price and Availability


USD 1050
USD 3650

USD 2650
USD 4450

USD 2950

Turofexorate isopropyl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 319832
Name: Turofexorate isopropyl
CAS#: 629664-81-9
Chemical Formula: C25H24F2N2O3
Exact Mass: 438.1755
Molecular Weight: 438.4748
Elemental Analysis: C, 68.48; H, 5.52; F, 8.67; N, 6.39; O, 10.95

Synonym: WAY-362450; WAY362450; WAY 362450; XL335; XL 335; XL-335; Turofexorate isopropyl.

IUPAC/Chemical Name: Isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino(4,5-b)indole-5- carboxylate


InChi Code: InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3

SMILES Code: O=C(C1=CN(C(C2=CC=C(F)C(F)=C2)=O)CC(C)(C)C3=C1NC4=C3C=CC=C4)OC(C)C

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Manley S, Ding W. Role of farnesoid X receptor and bile acids in alcoholic liver disease. Acta Pharm Sin B. 2015 Mar;5(2):158-67. doi: 10.1016/j.apsb.2014.12.011. Epub 2015 Mar 9. Review. PubMed PMID: 26579442; PubMed Central PMCID: PMC4629219.

2: Wu WB, Xu YY, Cheng WW, Wang YX, Liu Y, Huang D, Zhang HJ. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta--a study on maternal cholestasis model. Placenta. 2015 May;36(5):545-51. doi: 10.1016/j.placenta.2015.02.005. Epub 2015 Feb 17. PubMed PMID: 25747729.

3: Liu X, Xue R, Ji L, Zhang X, Wu J, Gu J, Zhou M, Chen S. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem Biophys Res Commun. 2014 Jul 18;450(1):117-23. doi: 10.1016/j.bbrc.2014.05.072. Epub 2014 May 27. PubMed PMID: 24875360.

4: Baghdasaryan A, Chiba P, Trauner M. Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med. 2014 Jun;37:57-76. doi: 10.1016/j.mam.2013.12.001. Epub 2013 Dec 12. Review. PubMed PMID: 24333169; PubMed Central PMCID: PMC4045202.

5: Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun. 2014 Jan 3;443(1):68-73. doi: 10.1016/j.bbrc.2013.11.057. Epub 2013 Nov 20. PubMed PMID: 24269813.

6: Li WH, Fu J, Zheng MY, Liu GX, Tang Y. [Progress in the ligands and their complex structures of farnesoid X receptor]. Yao Xue Xue Bao. 2012 Jun;47(6):704-15. Review. Chinese. PubMed PMID: 22919716.

7: Mehlmann JF, Crawley ML, Lundquist JT 4th, Unwalla RJ, Harnish DC, Evans MJ, Kim CY, Wrobel JE, Mahaney PE. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR). Bioorg Med Chem Lett. 2009 Sep 15;19(18):5289-92. doi: 10.1016/j.bmcl.2009.07.148. Epub 2009 Aug 3. PubMed PMID: 19683924.

8: Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009 Aug;51(2):380-8. doi: 10.1016/j.jhep.2009.03.025. Epub 2009 May 18. PubMed PMID: 19501927.

9: Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res. 2009 Jun;50(6):1090-100. doi: 10.1194/jlr.M800619-JLR200. Epub 2009 Jan 27. PubMed PMID: 19174369; PubMed Central PMCID: PMC2681391.

10: Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, Foster P, Li J, Pircher P, Petrowski M, Schulman I, Westin S, Wrobel J, Yan G, Bischoff E, Daige C, Mohan R. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009 Feb 26;52(4):904-7. doi: 10.1021/jm8014124. PubMed PMID: 19159286.

11: Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G543-52. doi: 10.1152/ajpgi.90585.2008. Epub 2009 Jan 8. PubMed PMID: 19136377.

12: Zhang S, Liu Q, Wang J, Harnish DC. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun. 2009 Feb 6;379(2):476-9. doi: 10.1016/j.bbrc.2008.12.117. Epub 2008 Dec 30. PubMed PMID: 19118524.